Avantor Schedules Q4 2025 Earnings Release and Conference Call
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 14 Jan 26
Source: Globenewswire
Avantor Inc (AVTR) saw a price decline of 5.04% as it crossed below its 5-day SMA amid a broader market downturn, with the Nasdaq-100 down 1.76% and the S&P 500 down 1.08%.
The company announced its Q4 and full-year 2025 earnings release scheduled for February 11, 2026, along with a conference call at 8:00 a.m. EST to discuss the financial results. This demonstrates Avantor's commitment to transparency and investor communication, aiming to bolster market confidence.
The upcoming earnings report is expected to provide insights into Avantor's performance, which serves over 300,000 customer locations globally, highlighting its leadership in the life sciences and advanced technology sectors.
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 12.30 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
2 Buy
9 Hold
2 Sell
Hold
Current: 11.650
Low
8.00
Averages
12.30
High
17.00
Current: 11.650
Low
8.00
Averages
12.30
High
17.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
